Key Takeaways
- A deliberate Q4 pause, not a demand collapse: Revenue fell to INR273 crores from INR302 crores YoY as management chose not to push advance placements into a falling-price market, preferring to preserve distributor health and set up Q1 FY25 growth.
- Profitability turned sharply on mix, not volume: EBITDA grew 33% and PAT grew 62% for the full year, driven by the Maharatna/value-added product focus; that segment rose from 51% to 59% of B2C and grew ~27%.
- The margin recovery story has a floor: The INR30-crore high-cost inventory drag that hit Q1 is now fully cleared, and raw material prices have touched bottom with some shortages emerging, removing a major headwind.
- Dahej backward integration is imminent: The plant is fully ready and awaiting final state clearances expected in 2-3 months; once running, it will reduce import dependence and add new technical-manufacturing AIs.
- What to watch next quarter: Whether the 20% volume growth internal target translates into actual Q1 placements, the pace of Dahej clearance, and any raw material price movement from the bottom.
The Q4 Pause: Why Revenue Fell
- Management chose not to push: Distributors lacked confidence to store material in a falling market and bought only for regular sales; the company did not press its team to place material in March, wanting to grow in Q1 of the next year instead.
- Seasonal and weather headwinds compounded it: March and February are acute winter months with hardly any season; a drought-like situation in the South, rain devastation in January/December, and no canal water further suppressed immediate demand.
- B2B suffered the same confidence deficit: Both international and domestic B2B demand was poor because the industry as a whole lacked confidence.
- The market has been falling for two years: The majority of the hit was taken in FY23, but some impact carried into FY24, particularly in Q1 and later stages; when the market is not stable, the company is forced to sell at lower prices, impacting the entire realization that should have come over the last two years.
Aggarwal: "The market did not have the confidence to store the material, so distributors bought only whatever they were having the regular sales, so they tried to skip the advance placements and we also did not place it strategically because we wanted to grow in the Q1 of the next year, so we did not push the market for that because the markets were falling."
Maharatna Strategy & Margin Delivery
- Maharatna drove the full-year profit story: The segment grew from 51% to 59% of B2C, delivering ~27% growth, while the company cut tail of old generic molecules that were building inventory and risk.
- Product mix shifted materially: Fungicides share rose from 12% to 19% while herbicides dropped from 40% to 33%, reflecting the deliberate pivot toward higher-margin, growth-outlook products.
- Tail-cutting removed loss-making generics: More than 6 or 7 AIs of generic products were cut in the last year; when prices fell, the company had made a loss on many of these, so it moved out of old molecules not seeing future growth.
- Maharatna qualification is disciplined: A product must have a 3-5 year growth outlook, a starting contribution of INR5-10 crores, and for focus Maharatna, margins of 30%-35% and sales of ~INR35 crores minimum in the first or second year.
- New launches lean toward proprietary registrations: ~75% of introductions will be 9(3) registrations and ~25% will be 9(4), reinforcing the shift toward differentiated, higher-margin products.
Aggarwal: "The product should be the growing product and it should see growth at least from next 3 to 5 years. And to start with, the contribution from the product should be in the range of at least INR5 crores to INR10 crores."
Raw Material & Pricing Dynamics
- Raw material prices have bottomed: Prices have already stabilized and touched the bottom, with a slight increase now visible from that floor; management does not see a fall coming again from here.
- Shortages are emerging as demand picks up: Some raw materials are in shortage; China is also not making margins and many factories there have stopped manufacturing various products, which has impacted availability and price in the current season when demand exists.
- Price outlook remains cautious: Despite the bottom, management envisages that prices on average will fall again this year, though certain products could see increases of 5%, 10%, or 15%.
- The high-cost inventory overhang is gone: Q1 had a dip of ~INR30 crores in profitability due to higher-cost inventories; with no high-cost inventory in the system now, profit is expected to go up.
Dahej Plant & OAT Agrio JV: The Medium-Term Build
- Dahej is ready, waiting on state clearances: The plant is fully ready and up to start function; central department clearance is done, state permissions are about to come, and management expects final clearances in 2-3 months.
- Backward integration is the strategic logic: The plant will help make certain raw materials in-house, reducing import dependence, and will introduce more AIs to manufacture technicals and launch brands.
- OAT Agrio JV product is in final data generation: The first product has been identified and scaled up; 80% of data is coming from Japan, 20%-25% is being generated in India, and data generation should complete in 2025 with final data from Japan by mid-2025.
- Market entry targeted for 2026: The company will submit the file immediately when data is received; the product should hit the market in 2026, or early 2027 if delayed, launching first in India and then taking it to the world market.
- Revenue potential is material but uncommitted: Management sees potential starting from INR50 crores and scaling to INR100, INR150, or INR200 crores, though it declined to sound aggressive to avoid changing analyst estimates.
Aggarwal: "I don't want to sound very aggressive because that will change earlier numbers, what you have in your books for us. So - but I can say it can have a potential of starting from INR50 crores, it can touch INR100 crores, INR150 crores, INR200 crores."
Growth Levers & Volume Ambition
- Internal volume target is 20%+: Management is planning nearly double-digit value growth, which requires ~20% volume growth because of price declines; the target is internal and the company declined to give formal guidance.
- B2C expected to sustain double-digit growth: The company anticipates at least 10% growth in the B2C segment, driven by new product launches and the Maharatna focus.
- New product engine is loaded: 6 to 7 new product launches are planned for FY25, targeting June and July; at least 3 to 4 new AIs should be introduced every year.
- Nissan partnership provides a steady pipeline: At least 1 product from Nissan is planned every year, with some years having 2; the pipeline with Nissan is strong.
- Exports will be a modest contributor: Export growth next year is seen at no more than 2% or 3%, constrained by international currency issues, country credit ratings, and dollar availability.
- Biologicals are a slow build: The segment may not double this year but will see decent growth; management expects it to become a decent segment in times to come, though no timeline was given.
Margin Path & Cost Structure
- Double-digit EBITDA is the stated goal: Management is working to take EBITDA margins back to double digits in the next 1 to 2 years, but declined to commit to a specific number like 14%-15%, saying it will go step-by-step with growth every quarter.
- Cost increases were operational, not structural: Other costs rose mainly from power and fuel factors and ~INR5 crores in additional traveling expenses for new product launches with farmers.
- No credit-note or write-off hit was taken: When asked directly, management confirmed there was no hit from credit note issuance to dealers or write-offs.
- Dahej margins should improve the mix: The margin profile for the new plant will be what the company is making now, but since it will introduce newer products, there will be some improvements; management offered to comment in writing.
Aggarwal: "Interesting question, but you cannot make - talk about jumps actually immediately. So I would also love to jump if there is an opportunity. But yes, there will be a good growth. Difficult to say that 14%, 15% in two years is, it's not easy. So we'll go step-by-step growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej plant operational | Final state clearances received, manufacturing begins | 2-3 months |
| New product launches | 6-7 products launched | June-July FY25 |
| OAT JV first product filing | Data generation complete, file submitted | Mid-2025 data; file immediately after |
| OAT JV first product market entry | Product launched in India first | 2026, or early 2027 if delayed |
| Volume growth | Internal target of 20%+ volume growth | FY25 |
| B2C growth | At least 10% growth | FY25 |
| Export growth | No more than 2%-3% growth | FY25 |
| Nissan product launches | At least 1 product per year | Annual, ongoing |
| New AI introductions | At least 3-4 new AIs per year | Annual, ongoing |
| EBITDA margin | Return to double digits | Next 1-2 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | ₹273 cr, vs ₹302 cr in Q4 FY23 |
| EBITDA | ₹0 cr, vs loss of ₹28 cr in Q4 FY23 |
| PAT | ₹5 cr, vs loss of ~₹29 cr in Q4 FY23 |
| FY24 revenue from operations | ₹1,966 cr, +9% YoY |
| FY24 EBITDA | ₹163 cr, +33% YoY |
| FY24 PAT | ₹102 cr, +62% YoY |
| FY24 volume growth | ~20%, value growth ~9%, prices fell ~10% |
| B2C revenue growth (FY24) | ~11% |
| B2B segment growth (FY24) | 5% |
| Maharatna share in B2C sales | 59%, up from 51% in FY23 |
| Insecticide share of revenue (FY24) | ~45%, unchanged YoY |
| Herbicide share of revenue (FY24) | 33%, down from 40% in FY23 |
| Fungicide share of revenue (FY24) | 19%, up from 12% in FY23 |
| B2C segment share of sales (FY24) | ~69% |
| B2B segment share of sales (FY24) | 26% |
| Export share of sales (FY24) | ~5% |
| Market share in B2C domestic | ~5% to 5.5% |
| Working capital base | 150, optimized from 169 |
| Debt equity ratio | 0.09%, improved from 0.18% |
| Advertisement and promotions expense | ₹25 cr to ₹30 cr annually |
| CWIP on balance sheet | ₹135 cr, major portion for Dahej L&T plant |
| New products launched in last 3-4 years contributed | ₹500+ cr |
| Q1 FY24 profitability dip from high-cost inventory | ~₹30 cr impact |
| Export growth expectation for next year | not more than 2% or 3% |
| Dahej plant expected to be fully functioning | in 2 to 3 months |